Citations

Clear

3942 citation(s) found for "To, Van".

A Versatile Protocol for Studying Calvarial Bone Defect Healing in a Mouse Model
Samsonraj, Rebekah M. , Dudakovic, Amel , Zan, Pengfei, Pichurin, Oksana , Cool, Simon M. , Wijnen, André J. van , van Wijnen, Andre J, van Wijnen, Andre J

Mayo Clinic

Tissue Engineering Part C: Methods | May 24, 2017 | Volume: 23 | Issue: 11 | Pages: 686-693

10.1089/ten.tec.2017.0205 | PMID 28537529 Get It

Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy
Stead, Matt, Lundstrom, Brian Nils, Lundstrom, Brian N. , Worrell, Gregory A. , Gompel, Jamie J. Van

Mayo Clinic

Expert Review of Neurotherapeutics | May 23, 2017 | Volume: 17 | Issue: 7 | Pages: 661-666

10.1080/14737175.2017.1331129 | PMID 28532252 Get It

A Combination of a Polycaprolactone Fumarate Scaffold with Polyethylene Terephthalate Sutures for Intra-Articular Ligament Regeneration
Parry, Joshua A. , Wagner, Eric R. , Kok, Peter L., Dadsetan, Mahrokh, Yaszemski, Michael J. , Wijnen, André J. van , van Wijnen, Andre J, Kakar, Sanjeev , van Wijnen, Andre J , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | May 20, 2017 | Volume: 24 | Issue: 3-4 | Pages: 245-253

10.1089/ten.tea.2016.0531 | PMID 28530131 Get It

Intranuclear and higher‐order chromatin organization of the major histone gene cluster in breast cancer
Fritz, Andrew J. , Ghule, Prachi N. , Tye, Coralee E. , Page, Natalie A., Hong, Deli , Shirley, David J. , Weinheimer, Adam, Gerrard, Diana L., Frietze, Seth , Wijnen, André J. van , Zaidi, Sayyed K. , Imbalzano, Anthony N. , Lian, Jane B. , Stein, Janet L. , van Wijnen, Andre J, Boyd, Joseph R. , Barutcu, A. Rasim , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | May 15, 2017 | Volume: 233 | Issue: 2 | Pages: 1278-1290

10.1002/jcp.25996 | PMID 28504305 Get It

Alterations in nuclear morphology are common in cancer progression. However, the degree to which gross morphological abnormalities translate into compromised higher‐order chromatin organization is poorly understood. To explore the functional links between gene expression and chromatin structure in breast cancer, we performed RNA‐seq gene expression analysis on the basal breast cancer progression model based on human MCF10A cells. Positional gene enrichment identified the major histone gene cluster at chromosome 6p22 as one of the most significantly upregulated (and not amplified) clusters of genes from the normal‐like MCF10A to premalignant MCF10AT1 and metastatic MCF10CA1a cells. This cluster is subdivided into three sub‐clusters of histone genes that are organized into hierarchical topologically associating domains (TADs). Interestingly, the sub‐clusters of histone genes are located at TAD boundaries and interact more frequently with each other than the regions in‐between them, suggesting that the histone sub‐clusters form an active chromatin hub. The anchor sites of loops within this hub are occupied by CTCF, a known chromatin organizer. These histone genes are transcribed and processed at a specific sub‐nuclear microenvironment termed the major histone locus body (HLB). While the overall chromatin structure of the major HLB is maintained across breast cancer progression, we detected alterations in its structure that may relate to gene expression. Importantly, breast tumor specimens also exhibit a coordinate pattern of upregulation across the major histone gene cluster. Our results provide a novel insight into the connection between the higher‐order chromatin organization of the major HLB and its regulation during breast cancer progression.
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, Jennifer L. , Höglinger, Günter U. , Antonini, Angelo , Bordelon, Yvette , Boxer, Adam L. , Eimeren, Thilo van , Golbe, Lawrence I. , Kassubek, Jan , Kurz, Carolin , Litvan, Irene , Pantelyat, Alexander , Rabinovici, Gil D. , Respondek, Gesine , Rominger, Axel , Rowe, James B. , Stamelou, María , Josephs, Keith A. , Group, for the Movement Disorder Society‐endorsed PSP Study, Stamelou, Maria , Colosimo, Carlo , Group, for the Movement Disorder Society‐endorsed PSP Study, Höglinger, Günter U , Antonini, Angelo , Rowe, James B , Litvan, Irene , Pantelyat, Alex , Rabinovici, Gil D , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | May 13, 2017 | Volume: 32 | Issue: 7 | Pages: 955-971

10.1002/mds.27038 | PMID 28500751 Get It

ABSTRACTPSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS‐SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five‐level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group‐level findings, level 2 representing biomarkers with demonstrable individual‐level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Respondek, Gesine , Kurz, Carolin , Arzberger, Thomas, Compta, Yaroslau , Englund, Elisabet , Ferguson, Leslie W. , Gelpí, Ellen , Irwin, David J. , Meissner, Wassilios G. , Pantelyat, Alexander , Rajput, Alex, Swieten, John C. van, Troakes, Claire , Josephs, Keith A. , Lang, Anthony E. , Mollenhauer, Brit , Müller, Ulrich , Whitwell, Jennifer L. , Antonini, Angelo , Bhatia, Kailash P. , Bordelon, Yvette , Corvol, Jean‐Christophe , Dodel, Richard , Kassubek, Jan , Krismer, Florian , Xiong, Chengjie , Lorenzl, Stefan , Morris, Huw R. , Nestor, Peter J. , Oertel, Wolfgang H., Rabinovici, Gil D. , Rowe, James B. , Eimeren, Thilo van , Wenning, Gregor K. , Boxer, Adam L. , Golbe, Lawrence I. , Litvan, Irene , Stamelou, María , Höglinger, Günter U. , Group, for the Movement Disorder Society‐Endorsed PSP Study, Meissner, Wassilios G , Bhatia, Kailash P , Stamelou, Maria , Höglinger, Günter U , Giese, Armin , Nilsson, Christer F. , Swieten, John C. van , Colosimo, Carlo , Grossman, Murray , Krismer, Florian , Group, for the Movement Disorder Society‐Endorsed PSP Study, Lang, Anthony E , Irwin, David J , Antonini, Angelo , Rowe, James B , Corvol, Jean-Christophe , Litvan, Irene , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Rabinovici, Gil D , Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | May 13, 2017 | Volume: 32 | Issue: 7 | Pages: 995-1005

10.1002/mds.27034 | PMID 28500752 Get It

ABSTRACTBackgroundProgressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes.ObjectiveTo identify clinical features and investigations that predict or exclude PSP pathology during life, aiming at an optimization of the clinical diagnostic criteria for PSP.MethodsWe performed a systematic review of the literature published since 1996 to identify clinical features and investigations that may predict or exclude PSP pathology. We then extracted standardized data from clinical charts of patients with pathologically diagnosed PSP and relevant disease controls and calculated the sensitivity, specificity, and positive predictive value of key clinical features for PSP in this cohort.ResultsOf 4166 articles identified by the database inquiry, 269 met predefined standards. The literature review identified clinical features predictive of PSP, including features of the following 4 functional domains: ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction. No biomarker or genetic feature was found reliably validated to predict definite PSP. High‐quality original natural history data were available from 206 patients with pathologically diagnosed PSP and from 231 pathologically diagnosed disease controls (54 corticobasal degeneration, 51 multiple system atrophy with predominant parkinsonism, 53 Parkinson's disease, 73 behavioral variant frontotemporal dementia). We identified clinical features that predicted PSP pathology, including phenotypes other than Richardson's syndrome, with varying sensitivity and specificity.ConclusionsOur results highlight the clinical variability of PSP and the high prevalence of phenotypes other than Richardson's syndrome. The features of variant phenotypes with high specificity and sensitivity should serve to optimize clinical diagnosis of PSP. © 2017 International Parkinson and Movement Disorder Society
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
Moghadasi, Setareh , Vreeswijk, Maaike P.G. , Janssen, Linda AM, Borg, Åke , Ehrencrona, Hans , Paulsson-Karlsson, Ylva, Wappenschmidt, Barbara , Engel, Christoph , Gehrig, Andrea, Hansen, Thomas van Overeem , Thomassen, Mads , Jensen, Uffe Birk , Kruse, Torben A., Ejlertsen, Bent , Gerdes, Anne‐Marie , Pedersen, Inge Søkilde , Caputo, Sandrine M. , Couch, Fergus J., Hallberg, Emily J., Ouweland, Ans MW van den, Collée, Margriet J., Teugels, Erik , Adank, Muriel A. , Luijt, Rob B. van der , Mensenkamp, Arjen R. , Oosterwijk, Jan C., Blok, Marinus J. , Janin, Nicolas, Claes, Kathleen , Tucker, Kathy , Viassolo, Valeria , Eccles, Diana , Devilee, Peter , Asperen, Christi J. van , Goldgar, David E., Gómez, E. , Meeks, Huong , Janssen, Linda A.M., Arnold, Norbert , Collée, Margriet , Toland, Amanda Ewart , Spurdle, Amanda B. , Eccles, Diana , Vreeswijk, Maaike P G , Claes, Kathleen B M , Ehrencrona, Hans , van der Luijt, Rob B , Engel, Christoph , van Asperen, Christi J , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Devilee, Peter

Mayo Clinic

Journal of Medical Genetics | May 11, 2017 | Volume: 55 | Issue: 1 | Pages: 15-20

10.1136/jmedgenet-2017-104560 | PMID 28490613 Get It

Background We previously showed that the BRCA1 variant c.5096G>A p.Arg1699Gln (R1699Q) was associated with an intermediate risk of breast cancer (BC) and ovarian cancer (OC). This study aimed to assess these cancer risks for R1699Q carriers in a larger cohort, including follow-up of previously studied families, to further define cancer risks and to propose adjusted clinical management of female BRCA1*R1699Q carriers. Methods Data were collected from 129 BRCA1*R1699Q families ascertained internationally by ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) consortium members. A modified segregation analysis was used to calculate BC and OC risks. Relative risks were calculated under both monogenic model and major gene plus polygenic model assumptions. Results In this cohort the cumulative risk of BC and OC by age 70 years was 20% and 6%, respectively. The relative risk for developing cancer was higher when using a model that included the effects of both the R1699Q variant and a residual polygenic component compared with monogenic model (for BC 3.67 vs 2.83, and for OC 6.41 vs 5.83). Conclusion Our results confirm that BRCA1*R1699Q confers an intermediate risk for BC and OC. Breast surveillance for female carriers based on mammogram annually from age 40 is advised. Bilateral salpingo-oophorectomy should be considered based on family history.
Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making
Flier, Wiesje M. van der , Kunneman, Marleen , Petersen, Ronald C. , Smets, Ellen M.A. , Bouwman, Femke H. , van der Flier, Wiesje M

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 9, 2017 | Volume: 3 | Issue: 3 | Pages: 301-304

10.1016/j.trci.2017.03.008 | PMID 29067336 Get It

Abstract The launch of the NIA‐AA research criteria for Alzheimer's disease (AD) diagnosis illustrates the large advances that have been made in the field of AD diagnosis. These new possibilities however also introduce new dilemmas into the consulting room, and this provides room for shared decision making (SDM). SDM refers to clinicians and patients (and/or their caregivers) working together to decide which care plan best fits individual patients and their lives, when there is more than one reasonable option. Here, we describe how SDM in the diagnosis of AD promotes patient‐centered care, as it helps to adapt the diagnostic process to the patients' values and preferences. We provide an outline for a research agenda, as SDM in the diagnosis of dementia should be studied intensively incorporating the views of both patients and caregivers.